Biomarker Testing to Optimize NSCLC Care: Multidisciplinary Perspectives
  • CME

Learn how experts optimally test for biomarkers in patients with NSCLC in this interactive text module with multidisciplinary perspectives from Matthew Gubens, MD, MS, a thoracic oncologist, and Craig Mackinnon, MD, PhD, an anatomical and molecular pathologist, and then use the results to integrate novel and emerging targeted therapies effectively and safely into clinical practice care.
Matthew Gubens, MD, MS
Craig Mackinnon, MD, PhD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: July 6, 2022 Expiration: July 5, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess current molecular biomarker guideline recommendations along with new and emerging predictive biomarkers to guide precision treatment decisions in patients with NSCLC
  • Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays and other nuances
  • Identify clinically appropriate testing for all appropriate currently available biomarkers to guide treatment selection and clinical trial eligibility for patients with NSCLC
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in patients with lung cancer
  • Identify best practices and strategies for interdisciplinary collaboration/coordination among pathologists and oncologists regarding cancer biomarker testing and interpretation of results to guide clinical decisions

Acknowledgements

Provided by Clinical Care Options, LLC in partnership with the Association for Molecular Pathology

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

In partnership with
Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Daiichi Sankyo, Inc.
Genentech
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Lilly
Novartis Pharmaceuticals Corporation

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Craig Mackinnon, MD, PhD

Professor
Direct Division of Genomic Diagnostics and BioInformatics
University of Alabama at Birmingham
Birmingham, Alabama

Craig Mackinnon MD, PhD, has no relevant financial relationships to disclose.
Matthew Gubens, MD, MS

Associate Professor
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Genzyme/Sanofi, iTeos, Surface; research support: Amgen, Celgene, Johnson & Johnson, Merck, Novartis, Trizell.

Staff

Kemi Obajimi, PhD

Scientific Director

Kemi Obajimi, PhD, has no relevant financial relationships to disclose.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant financial relationships to disclose.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant financial relationships to disclose.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer has no relevant financial relationships to disclose.
Brian Purves
Brian Purves, PharmD, MBA, has no relevant financial relationships to disclose.
Justine Stanley

Editorial Contributor

Justine Stanley has no relevant financial relationships to disclose.
Krista Marcello

Associate Director, Educational Strategy

Krista V. Marcello has no relevant financial relationships to disclose.
Kristen Morrow, PhD

Editorial Contributor

Kristen Morrow, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for pathologists, oncologists, and other healthcare professionals who care for patients with lung cancer.

Goal

The goal of this program is to improve the knowledge, confidence, and competence of learners in the use of biomarkers to select individualized treatments for patients with NSCLC.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 06, 2022, through July 05, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Experts highlight key studies being presented at the upcoming 2022 WCLC annual meeting in this commentary from Clinical Care Options (CCO)

Wade T. Iams, MD, MSCI Heather Wakelee, MD Released: August 5, 2022

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered malignancies.

Alexander Drilon, MD
Program Director
Thomas Stinchcombe, MD
Program Director
Released: August 4, 2022

Downloadable slideset on the molecular determinants for the selection of optimal therapy for patients with NSCLC, from Clinical Care Options (CCO)

Matthew Gubens, MD, MS Craig Mackinnon, MD, PhD Released: July 29, 2022

Video featuring nursing perspective on biomarker testing in NSCLC and targeted therapy for actionable genomic alterations, from Clinical Care Options (CCO)

person default Beth Sandy, MSN, CRNP Elizabeth S. Waxman, BSN, MSN, ANP-BC Registered Nurses: 1.0 Nursing contact hour Released: July 27, 2022 Expired: July 26, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings